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Background: One of the most important biological characteristics of Glioblastoma multiforme (GBM) is high
vascular density. Vadimezan (ASA404, DMXAA) belongs to the class of small molecule vascular disrupting agents
(VDA) that cause disruption of established tumor vessels and subsequent tumor hemorrhagic necrosis. Its selective
antivascular effect is mediated by intratumoral induction of several cytokines including tumor necrosis factor-α
(TNF-α), granulocyte-colony-stimulating factor (G-CSF), interleukin 6 (IL-6) and macrophage inflammatory protein
1α (MIP-1α). Preclinical studies have demonstrated that ASA404 acts synergistically with taxanes. In this study, we
investigated if treatment of mice bearing U251 human glioblastoma xenografts with ASA404 and taxol may be
synergistic. Therapy response was evaluated by measuring changes in tumor size and metabolic activity using
18F-FDG PET (Fluorodeoxyglucose - positron emision tomography) imaging.
Methods: U251 cells were inoculated s.c. in the right hind limb of NMRI-Foxn1nu athymic female nude mice.
Animals were randomly assigned into 4 groups (7–9 animals/group) for treatment: control, taxol, ASA404, and
ASA404 plus taxol. The animals received either a single dose of taxol (10 mg/kg), ASA404 (27.5 mg/kg), or taxol
(10 mg/kg) plus ASA404 (27.5 mg/kg) administered i.p.; ASA404 was administred 24 h after the treatment with
taxol. 4 and 24 h after treatment with ASA404 (28 and 48 h hours after treatment with taxol) 18 F-FDG PET scans
were performed.
Results: The treatment with taxol did not affect the tumor growth in comparison to untreated controls. The
treatment of animals with single dose ASA404 alone or in combination with taxol caused a significant delay in
tumor growth. The combined treatment did not decrease the growth of the xenografts significantly more than
ASA404 alone, but early changes in tumor 18 F-FDG uptake preceded subsequent growth inhibition. The tumor
weights, which were determined at the end of treatment, were lower in case of combined treatment.
Conclusions: The treatment with ASA404 alone or in combination with taxol showed antitumoral effects in our
glioblastoma model probably through destruction of blood vessels. The implications for the anticancer effect of this
compound warrant further preclinical studies. 18F-FDG PET appears to be a promising tool to monitor treatment
with ASA404 early in the course of therapy.* Correspondence: dusan.milanovic@uniklinik-freiburg.de
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Glioblastoma multiforme (GBM) is the most common
brain tumour of astrocytic origin [1]. Despite the use of
multimodal therapy (surgery and radiochemotherapy with
Temozolomide) the prognosis of patients with this highly
aggressive neoplastic disease remains poor with a median
survival time of 14.6 months [2]. One of the most import-
ant biological characteristics of GBM is high vascular
density. Thus targeting the vasculature in this tumour
could be an attractive therapeutic strategy [3]. Bevacizu-
mab is a monoclonal antibody against VEGF (Vascular
Endothelial Growth Factor), which is one of key proteins
stimulating the growth of new blood vessels (angiogen-
esis) in glioblastomas [4]. This drug was granted acceler-
ated approval by the US Food and Drug Administration
(FDA) as a single agent in recurrent GBM [5].
5,6-Dimethylxanthenone-4-Acetic Acid (ASA404,
DMXAA) belongs to the class of small molecule vascu-
lar disrupting agents (VDA) that, differently to antian-
giogenic agents, cause disruption of established tumor
vessels by induction of apoptosis in endothelial tumour
cells what is followed by rapid vascular collapse and sub-
sequent tumor hemorrhagic necrosis [6]. The mechan-
ism of the selective antivascular effect of ASA404 in the
tumor vasculature is not well understood but it has been
proposed that these effects are mediated by intratumoral
induction of several cytokines including tumor necrosis
factor-α (TNF-α), granulocyte-colony-stimulating factor
(G-CSF), interleukin 6 (IL-6), macrophage inflammatory
protein 1α (MIP-1α) [7,8], increased plasma serotonin
concentration [9] and induction of intratumoral nitric
oxide synthase [10]. In addition to antivascular effects,
ASA404 has an antiangiogenic effect mediated by induc-
tion of the antiangiogenic chemokine interferon-inducible
protein 10 (IP-10) which inhibits basic fibroblast growth
factor-induced neovascularization in several models
in vitro and in vivo [11]. Preclinical studies have demon-
strated that ASA404 acts synergistically with severeral con-
ventional chemotherapeutic agents. The most pronounced
synergistic effect was observed when ASA404 was com-
bined with taxane [12]. Taxol is a mitotic inhibitor which is
used in the therapy of many neoplastic diseases. It binds
and stabilizes microtubules by inhibiting tubulin
depolarization and causing cell cycle arrest in the G2/M
Phase [13]. In addition to its cytostatic effect on cancer
cells, taxol (at lower concentrations) inhibits endothelial
cell function related to angiogenesis [14]. It has been
shown that taxol delays growth of human GBM xenografts
[15] and we hypothesized that combined treatment with
ASA404 may be synergistic in mice bearing U251 human
glioblastoma xenografts. An additional aim of thisstudy
was to examine if non-invasive imaging using 18 F-FDG –
PET (Fluorodeoxyglucose–positron emision tomography)
may allow early assessment of tumor response to therapy.Methods
Animals
All animal experiments were performed in accordance
with the German Animal License Regulations and were
approved by the animal care committee of the Regier-
ungspräsidium Freiburg (registration number: G-08-59).
Athymic female nude mice NMRI-Foxn1nu (aged
6 weeks) were obtained from Taconic Europe (Bomholt-
gard, Denmark) and tumors were induced by inoculation
of 1.5 × 106 human glioblastoma (U251) cells s.c. into
the right hind limb. Palpable U251 xenografts developed
within 8 to 10 days.
Drug treatment
ASA404 was kindly provided by Novartis Pharma AG
Basel, Switzerland. ASA404 powder was dissolved in
phosphate buffered saline directly prior to administra-
tion. Stock solution of taxol (Sigma-Aldrich, Taufkirchen,
Germany) was prepared using dimethylsulfoxide
(DMSO) as the vehicle and appropriately diluted in saline
before treatments. Animals with 10 days-old xenografts
were randomly assigned in 4 groups (7–9 animals/group)
for treatment: control, taxol, ASA404 and ASA404 plus
taxol. The animals received either a single dose of taxol
(10 mg/kg), ASA404 (27.5 mg/kg), or taxol (10 mg/kg)
plus ASA404 (27.5 mg/kg) administered i.p.; ASA404
was administred 24 h after the treatment with taxol. Ani-
mals in the control group were treated with DMSO i.p.
Animal weight was measured daily. In order to determine
tumor volume by external caliper, the greatest longitu-
dinal diameter (length) and the greatest transverse diam-
eter (width) were determined. Tumor volume based on
caliper measurements was calculated by the modified el-
lipsoidal formula:
Tumor volume ¼ 1
2
length width2 
15 days after initiation of treatment animals were sacri-
ficed following the IACUC guidelines.
Xenografts were surgically excised and their weights
were measured.
PET scanning
PET imaging was performed with a microPET focus 120
small animal PET scanner (Concorde, Knoxville, TN).
After 4–8 h of fasting, 7.4 MBq 18 F-FDG was injected
via a lateral tail vein. For 18 F-FDG injection and imaging
the mice were anesthesised with 1.5–2% Isoflurane. PET
imaging was started 60 min after injection. Image acqui-
sition time was 10 min. Images were corrected for dead-
time and randoms and reconstructed by the routine
OSEM2D (2-Dimensional Reconstruction) algorithm
provided by the manufacturer. Image counts per pixel
per second were calibrated to activity concentrations
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with a known concentration of 18 F-FDG [16,17]. The
resolution of the reconstructed images ranged between
1.5-2 mm depending on the distance from the center of
the field of view [18]. 18 F-FDG uptake by the tumor
xenografts, brain and liver was quantified by maximum
standardized uptake values (SUVs) normalized to the
weight of the animals. Quantitative analysis was per-
formed with the Amide software [19]. In order to iden-
tify the maximum tumor 18 F-FDG uptake large ellipsoid
regions of interests were drawn around the whole tumor
area and organ, respectively. The voxel with the max-
imum 18 F-FDG uptake was then identified automatically
by the Amide software.Treatment days
Figure 1 The effect of taxol and ASA404 as sole agents or in
combination on body weight of mice. One day after treatment
with ASA404 alone or in the combination with taxol temporary
weight loss of animals was observed. Three days after treatment
with ASA 404, animal body weight had normalised compared to the
control group or the group which was treated only with taxol. By
the end of observation period, no significant difference in body
weight between control group and treated animals was observed.Statistical analysis
Mann–Whitney U test was used to compare quantifica-
tion data. Statistical analysis was conducted with Statis-
tical Package for Social Sciences software (SPSS Inc.).
We used a 2-sided significance level of 0.05 for all statis-
tical analyses.Results
Tolerability of treatment
The treatment with taxol as a sole compound was well
tolerated. No side effects were observed. In animals,
which were treated with ASA404 alone or in combiana-
tion with taxol, slight diarrhea and significant weight
loss were observed after 1 day of treatment with
ASA404 with full recovery by 3 days [Figure 1]. Weights
of animals remained relatively constant for the rest of
the experimental period.Activity of ASA404 and taxol on the growth and weight
of U251 human glioblastoma xenografts
The treatment with taxol did not affect the tumor growth
in comparison to untreated controls. The treatment of
animals with single dose ASA404 alone or in combination
with taxol caused a significant decrease in tumor volume
[Figure 2A]. At the completion of the study, weights of
the excised tumors were: control = 764± 168 mg,
taxol = 651± 148 mg, ASA404= 283± 127 mg, ASA404+
taxol =180± 56 mg. ASA404 as a sole agent caused a sig-
nificant decrease in tumor weight. In case of combined
treatment, statistically significant lower tumor weight was
observed compared to treatment with ASA404 as a single
agent (p= 0.0198) [Figure 2B]. Already 8 h after treatment,
xenografts in animals treated with ASA404 alone
[Figure 3C] or in combination with taxol [Figure 3D] re-
markably changed color. This change was not observed in
untreated animals [Figure 3A] or in animals which were
treated only with taxol [Figure 3B].PET
The treatment with taxol did not affect the 18 F-FDG up-
take in comparison to untreated controls. However, the
treatment of animals with ASA404 caused a rapid and
marked decrease in tumor 18 F-FDG uptake already 4 h
after treatment with ASA404 (p = 0.0495 - three mice in
each group). There was a similar decrease in 18 F-FDG
uptake at 24 h after treatment with ASA404 (p = 0.0455)
The combined therapy with ASA404 and taxol showed
significant reduction of the 18 F-FDG uptake, too, com-
parable to the one observed with ASA404 alone. Be-
tween 1–12 h after this investigation, several mice
treated with ASA404 alone or in combination with taxol
died. However, no significant change of 18 F-FDG uptake
was observed in the brain [Figure 4B] and liver
[Figure 4C] in ASA404 treated animals in comparison to
untreated control. No mice died in groups which were
not used for PET studies and which were treated with
the same drugs respectively, but a transient significant
weight loss was observed in all ASA404 treated animals.
Discussion
Despite intensive research and development of new tar-
geted therapies and radiotherapeutic techniques, progno-
sis for patients with GBM remains poor indicating the
need for new therapeutic approaches. Because of high vas-
cular density of these tumors development of therapies se-
lectively targeting the tumor vasculature may be
meaningful. The aim of this study was to identify if the
combined treatment with ASA404 and taxol shows syner-
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Figure 2 The effect of taxol and ASA404 as sole agents or in
combination on xenograft volume at different time points [A]
and weight [B] at the end of treatment. The treatment of animals
with taxol did not affect xenograft growth in comparison to
untreated controls. Treatment with ASA404 alone or in combination
with taxol caused significant growth delay of tumors in comparison
to control or animals which were treated with taxol as a sole
compound. There was not significant difference in tumor growth
delay between animals which were treated with ASA404 alone or in
combination with taxol. On the end of the treatment, the tumor
weight of animals treated with the ASA404 and taxol combination
were significantly lower than from animals which were treated only
with ASA 404.
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could be used to monitor tumor response early in the
course of therapy. Tumors of animals which were treated
with ASA404 as a sole agent or in combination with taxol
showed significant growth delay in comparison with con-
trol or animals which were treated only with taxol. Com-
bined treatment with taxol and ASA404 had a similar
effect on tumor growth as ASA404 alone. At the comple-
tion of the study, there was only slight but statically sig-
nificant difference in tumor weight for animals treated
with the drug combination as compared to animalsreceiving ASA404 alone. This difference in statistical sig-
nificance between the two parameters which were ana-
lysed (tumor volume and tumor weight) can be explained
by the use of a formula in which one important parameter
of the tumor growth – tumor depth, was not considered.
The tumor weights were determined only at the end of
treatment and in this may represent a more precise par-
ameter to determine an effect of the therapy. On the other
hand, the differences among treatment groups were very
small. Thus, based on these data, it is difficult to conclude
if combined treatment was synergistic. GBM represents
one of the most vascularized tumors [20]. Antiangiogenic
agents, such as bevacizumab, which is approved for treat-
ment of recurrent GBM patients who have failed previous
temozolomide and radiation therapy, inhibit new blood
vessel formation from preexisting vasculature [5]. Furthe-
more, antiangiogenic agents can normalize the tumor vas-
culature and decrease interstitial fluid pressure, providing
an improved drug delivery [21].
In contrary to antiangiogenic agents, VDAs such a
ASA404, have a selective affinity to existing tumor blood
vessels inducing their collapse which impairs blood flow,
oxygen supply and consequently causes necrosis in
tumor tissue [22].
The synergistic mechanism between ASA404 and taxol
seems not to involve potentiation of the vascular dis-
rupting activity of ASA404 or a pharmacokinetic inter-
action between these two drugs. The synergism might be
explained by complementary action against the different
subregions of the tumor; ASA404 is more active in the
poorly vascularized regions while taxol is active in the
well vascularized regions [12]. In addition to its direct
cytotoxic effects, taxol can induce the expression of pro-
inflammatory cytokines, such as TNF-α and IL-6 [23]
which are important mediators of ASA404 activity [7,8].
Thus, taxol and ASA404 can induce of same cytokines
which are responsible for tumor vascular disruption.
It has been reported that chemotherapy drugs should
be administered before, or shortly after ASA404 in order
to avoid compromised delivery. When taxol was admi-
nistred 4 h after ASA404, considerable loss of antitumor
activity has been observed apparently caused by
decreased blood flow which may inhibit taxol distribu-
tion in tumor tissue [12].
As opposed to conventional antineoplastic agents,
effects of VDAs such as ASA404 do not result in dra-
matic changes in tumor volume [22,24]. This indicates
that new approaches are necessary to monitor tumor re-
sponse to VDAs. We found that 18 F-FDG uptake
decreased rapidly after administration of ASA404. This
result is consistent with findings that highest increase of
intratumoral TNF-α activity is also observed 4 h after
tratment with ASA404 [25]. We suppose that the
marked reduction in tumor 18 F-FDG uptake is at least
B. TAX
D. ASA 404 + TAXC. ASA 404
A.Control
Figure 3 Color change of xenografts 32 h after the treatment with taxol [B], 8 h after the treatment with ASA404 [C] or 32 h after the
treatment with taxol plus a ASA404 during the last 8 h [D]. Xenograft [A] represents an untreated control. Treatment with ASA404 as a
sole agent or in combination with taxol most probably caused change of permeability and selective disruption of blood vessels within tumors
followed by hemorrhagic necrosis.
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seems likely that a significant fraction of tumor cells will
become necrotic, if perfusion is decreased to such an ex-
tent that 18 F-FDG uptake significantly decreases. Pre-
clinical studies in different tumor models have
demonstrated that ASA404 directly disrupts the tumor
vasculature by selectively inducing apoptosis in tumor-
vascular endothelial cells [26,27]. On the other hand, the
reason why several of the mice who underwent PET im-
aging died within several hours after the PET scan is not
entirely clear. Because of ASA404 antivascular proper-
ties, we presumed that bleeding might cause this effect.
Suprisingly, mouse dissection did not show any bleeding
source. There is only one report on the use of small ani-
mal PET as a biomarker for response to ASA404 [28]. In
this case, 18 F-fluromisonidazole (FMISO) PET imaging
was conducted and no side effects have been reported.
Before application of the 18 F-FMISO tracer, the animals
do not have to fasten.
It has been shown that the administration of TNF-α,
which is an important mediator of ASA404 antitumoral
action, decreases serum glucose levels in mice [29]. For
improving tumor visualization, mice have to fasten a18 F-FDG injection uptake period [30]. We speculate that
the combination of ASA404 mediated TNF-α secretion
with starving and anesthesia for PET investigation may
have caused death of mice.
It has been reported that treatment of nude mice bearing
U87 and GL261 orthotopically grown human glioblastoma
cells with ASA404 caused statistically significant increase in
median survival compared to untreated controls [31].
Measurement with contrast-enhanced magnetic resonance
imaging (MRI) and diffusion-weighted MRI which were
used to determine tumor blood flow 24 h after treatment
with ASA404 clearly demonstrated extravasation and accu-
mulation of the contrast agent in the tumor indicating
treatment-induced vascular disruption. Similar effects were
observed in fibrosarcoma (MCA205) ectopic and orthoto-
pic tumor models. Remarkably, 3 h after treatment with
ASA404 ectopic tumors showed 6-fold greater induction of
TNF-α compared to orthotopic tumors [32]. In our glio-
blastoma U251 model, the rapid mode of action of ASA404
became also apparent by the changes in tumor color 8 h
post injection which indicates hemorrhagic necrosis.
It is believed that VDAs are more effective against ves-
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Figure 4 SUV for tumor [A], brain [B] and liver [C] 4 and 24 h after treatment with ASA 404. Small animal FDG-PET imaging (frontal and
saggital sections) 4 h after treatment with taxol [E], ASA404 [F] or TAX+ASA404 [G]. [D] represents an untreated control. The treatment of
animals with ASA404 caused a marked decrease of the 18 F-FDG uptake which existed also 24 h after treatment with same compound. In case of
combined therapy the same effect was observed. No significant change of 18 F-FDG uptake was observed in the brain [Figure 4B] and the liver
[Figure 4C] in ASA404 treated animals in comparison to untreated control. The treatment with taxol as a sole compound did not influence
significant change of SUVs.
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ment [33,34].
In our experiments, tumors of animals which were trea-
ted with ASA404 as a sole agent or in combination with
taxol, showed significant growth delay in comparison with
control or animals which were treated only with taxol. In
both group of ASA404-treated animals, tumor start to re-
growth between 11 und 13 days after treatment.
Despite the significant smaller tumors, 20 days after
treatment, histopathologic examination revealed that all
treated tumors maintained the characteristic growth of
glioblastoma without any difference between the differ-
ent treatment groups (data not shown). No significant
increase in the level of cell death occured in tumors of
animals treated with ASA404 indicating that surviving
tumor cells were able to proliferate causing tumor re-
growth. In the Colon 38 adenocarcinoma tumor model[35], the antitumor effect of ASA404 was schedule-
dependent. 100% of the tumors regressed, when the
mice were treated with loading (25 mg/kg) and two sup-
plementary (5 mg/kg) doses after 4 and 8 h while in
mice treated with a single dose of ASA404 (25 mg/kg)
40% of tumors regressed. We supose that with a pro-
longed therapy better antitumoral responses might be
achieved. The first clinical data obtained from I/II phase
clinical trials evaluating ASA404 in combination with
taxol and carboplatin in patients with untreated
advanced non-small lung cancer were promising [36]
but in one large, randomized phase III placebo controled
trial, these results were not confirmed [37].
Conclusions
We conclude that treatment with ASA404 showed sig-
nificant antitumoral effects in our glioblastoma model.
Milanović et al. BMC Cancer 2012, 12:242 Page 7 of 8
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other glioblastoma models and in combination with con-
ventional antineoplastic drugs such are temozolamide
and carmustine standardly used in the treatment of glio-
blastoma. Further understanding the mechanisms of
VDAs for treatment optimization is necessary. If the tox-
icity associated with the 18F-FDG PET examination
would not occur in tumor patients, 18F-FDG PET could
be a promising tool to monitor the drug effects in the
clinic early in the course of therapy.
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